glp 1 and alcohol consumption GLP-1 Anti-Obesity Rx and Substance Use Disorders GLP-1 receptor agonists may protect

3 In a placebo-controlled study of 149 subjects, the group receiving phosphatidylserine outperformed the placebo group in performance tests related to daily memory tasks

Dose-by-dose weight loss in Phase 2 (NEJM) Phase 2 NEJM weight loss by dose, 24 and 48 weeks Dose 1 mg 24 weeks -7.2% 48 weeks -8.7% Dose 4 mg 24 weeks -12.9% 48 weeks -17.5% Dose 8 mg 24 weeks -15.7% 48 weeks -22.8% Dose 12 mg 24 weeks -17.5% 48 weeks -24.2% Dose Placebo 24 weeks -1.6% 48 weeks -2.1% Source: Jastreboff et al., NEJM 2023

Cagrilintide and Semaglutide differ fundamentally in receptor targeting

HCG co-administration helps maintain ITT during TRT, supporting continued spermatogenesis and preserving fertility